文献速递神经免疫

自体造血干细胞移植与阿仑单抗及奥瑞珠单抗治疗复发型多发性硬化的疗效比较:单中心队列研究

Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study.
PubMed 文献 · Ann Neurol · 2025-04-19

该单中心观察性队列研究纳入621例复发缓解型多发性硬化患者,分别接受自体造血干细胞移植(AHSCT,n=103)、阿仑单抗(ATZ,n=204)或奥瑞珠单抗(OCR,n=314)治疗,中位随访分别为43、43和32个月。结果显示AHSCT在预防复发方面优于ATZ和OCR,对MRI活动的抑制优于ATZ但与OCR相似,而残疾进展风险在三组间相似。

要点

  • AHSCT较ATZ显著降低5年随访的年化复发率、复发风险和MRI活动风险。
  • AHSCT较OCR显著降低3年随访的年化复发率,复发风险有降低趋势但无统计学意义。
  • AHSCT与OCR的新发MRI活动率相似(均为6%),EDSS进展风险在三组间相似。

核心结论

  • AHSCT较ATZ和OCR更有效地预防复发,对MRI活动的抑制强于ATZ但与OCR相似,三组残疾累积风险相似。

研究设计与样本

  • 来自英国伦敦某医院的观察性队列,建模数据来自621例复发缓解型多发性硬化患者,接受AHSCT(n=103)、ATZ(n=204)或OCR(n=314),中位随访分别为43、43和32个月。

主要发现

  • 5年随访时,AHSCT组 vs ATZ组的平均年化复发率为0.026 vs 0.087(p<0.001),复发风险HR 0.29(95%CI 0.13-0.63;p=0.002),MRI活动风险HR 0.33(95%CI 0.15-0.72;p=0.006),AHSCT组均显著更低。
  • 3年随访时,AHSCT组 vs OCR组的年化复发率为0.028 vs 0.073(p=0.02),AHSCT组显著更低;复发风险HR 0.45(95%CI 0.18-1.14;p=0.09),有降低趋势但无统计学意义。
  • AHSCT组与OCR组的新发MRI活动率相似(均为6%),HR 0.86(95%CI 0.28-2.67;p=0.80)。
  • EDSS进展风险在AHSCT组与ATZ组(HR 1.19,95%CI 0.71-2.00;p=0.50)及OCR组(HR 1.08,95%CI 0.57-2.04;p=0.82)间相似。

临床怎么用

  • 对于复发型多发性硬化患者,AHSCT在预防复发方面可能优于ATZ和OCR,但需注意随访时间较短且为观察性数据。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare clinical and radiological outcomes among relapsing multiple sclerosis patients treated with autologous hematopoietic stem cell transplantation (AHSCT), alemtuzumab (ATZ), and ocrelizumab (OCR). METHODS: From a London (UK) hospital-based observational cohort, modeled data were obtained from 621 relapsing-remitting multiple sclerosis patients, who were treated with AHSCT (n = 103), ATZ (n = 204), and OCR (n = 314), and were followed up for 43, 43, and 32 median months, respectively. The annualized relapse rate, new magnetic resonance imaging (MRI) lesions, and disability progression on Expanded Disability Status Scale were assessed. RESULTS: AHSCT showed superior efficacy compared with ATZ and OCR. After 5-year follow up, the mean annualized relapse rate (0.026 vs 0.087; p < 0.001), the risk of relapses (HR 0.29, 95% CI 0.13-0.63; p = 0.002), and of MRI activity (HR 0.33, 95% CI 0.15-0.72; p = 0.006) were significantly lower in AHSCT versus ATZ group. Compared with OCR, after 3-year follow-up AHSCT showed a significantly lower annualized relapse rate (0.028 vs 0.073; p = 0.02) and a trend to reduced risk of relapse (HR 0.45, 95% CI 0.18-1.14; p = 0.09), but similar low rates (6%) of new MRI activity (HR 0.86, 95% CI 0.28-2.67; p = 0.80). In addition, there was a similar risk of Expanded Disability Status Scale progression in AHSCT, and both ATZ (HR 1.19, 95% CI 0.71-2.00; p = 0.50) and OCR (HR 1.08, 95% CI 0.57-2.04; p = 0.82) groups. INTERPRETATION: AHSCT was followed by greater prevention of relapses compared with ATZ and OCR, and suppressed more profoundly MRI activity than ATZ, but similarly to OCR, albeit with shorter follow up. The risk of accumulating disability was similar among the treated groups. Studies with larger sample sizes and longer follow up may enable confirmation of these findings or detection of any additional differential effects. ANN NEUROL 2025;98:294-307.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Muraro PA, Zito A, Signori A, et al. Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study. Ann Neurol. 2025. PMID: 40251896. doi:10.1002/ana.27247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。